| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e472e52510b9a0150fb8bb983e5c5a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46e80b0e165c65d5b0ea9b1c8d6afe27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93295c2765fa5e67df1f8bb47331eeb1 |
| publicationDate |
2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2019059769-A |
| titleOfInvention |
Induced exon inclusion in spinal muscular atrophy |
| abstract |
The object is to provide induced exon inclusion in spinal muscular atrophy. The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment of spinal muscular atrophy (SMA). More specifically, the present invention relates to the induction of exon 7 inclusion to restore the level of survival motor neuron (SMN) protein encoded by the survival motor neuron (SMN) gene. Also within the scope of the invention is a method of treating spinal muscular atrophy (SMA) in a patient. Such a method comprises administering to the patient an antisense oligonucleotide comprising a nucleotide sequence of sufficient length and complementarity to specifically hybridize to a region within the SMN2 gene, and containing exon 7 within the cell. Including the step of enhancing the levels of SMN2 mRNA to exon deleted SMN2 mRNA. 【Selection chart】 None |
| priorityDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |